TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34217889
Drug: Cognitive-behavioral therapy-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy-based pain coping skills training with optional opioid taper support (18 telephone sessions over 52 weeks)
Study: 34217889
Drug: Cognitive-behavioral therapy-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy-based pain coping skills training with optional opioid taper support
Study: 34842343
Drug: Omega 3
Normalized name: omega 3,6
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omega 3 fatty acids 1000 mg/day for 6 months
Study: 35568494
Drug: COT (Conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: COT (Conventional Occupational Therapy)
Study: 35568494
Drug: COT+CCH (Conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: COT+CCH (Conventional Occupational Therapy + Chinese Calligraphy Handwriting)
Study: 35568494
Drug: COT+GRASP (Conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: COT+GRASP (Conventional Occupational Therapy + Graded Repetitive Arm Supplementary Program)
Study: 33345396
Drug: Chemotherapy (docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (docetaxel or paclitaxel)
Study: 32794176
Drug: Transnasal Humidified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transnasal Humidified Rapid‐Insufflation Ventilatory Exchange (THRIVE) with 100% oxygen at 70 l min−1 during apnoea
Study: 32738099
Drug: Dinaciclib (6-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinaciclib (6-12 mg/m2 i.v.) and MK-2206 (60-135 mg p.o.) weekly
Study: 32738099
Drug: Dinaciclib (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinaciclib (9 mg/m2) and MK-2206 (135 mg) at recommended dose
Study: 32738099
Drug: Dinaciclib and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinaciclib and MK-2206 combination
Study: 35144911
Drug: Drug trials
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug trials in GP practices
Study: 36006207
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BoNT‐A) injection (50 U)
Study: 32666576
Drug: Multi-professional medication
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-professional medication review (MPMR) service
Study: 35132024
Drug: Gabapentin enacarbil
Normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin enacarbil 600 mg twice daily starting the day before surgery continuing for 3 days thereafter
Study: 32841256
Drug: Micronutrient supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient supplement
Study: 34591227
Drug: IRLA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRLA with heated lidocaine gel (20 mL 2% lidocaine gel at 40 ℃)
Study: 34591227
Drug: IRLA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRLA with room temperature lidocaine gel (20 mL 2% lidocaine gel)
Study: 32265417
Drug: ANG-3777 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANG-3777 (2 mg/kg, 3 once-daily IV infusions)
Study: 32282539
Drug: Prescribing biologics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribing biologics over immunosuppressants based on risk factors
Study: 32282539
Drug: Endoscopy-driven treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopy-driven treatment in long-standing disease after failure of thiopurines
Study: 32282539
Drug: Endoscopy-driven treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopy-driven treatment in elderly patients
Study: 35273223
Drug: Newly designed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Newly designed patch fabricated by blending poly(L-lactic acid) and poly(ε-caprolactone) exposed to amniotic fluid for 16 weeks
Study: 35273223
Drug: Newly designed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Newly designed patch fabricated by blending poly(L-lactic acid) and poly(ε-caprolactone) exposed to phosphate-buffered saline (PBS) for 16 weeks
Study: 34535165
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) at a dose of 400 mg/daily for 8 weeks
Study: 33208014
Drug: Anti‐CCP therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti‐CCP therapy (negative control group)
Study: 35332737
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group 1
Study: 35332737
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group 2
Study: 36281151
Drug: TXA +
Normalized name: Tranexamic acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TXA + DEXA (15 mg/kg TXA before skin incision and 3 hours later; 20 mg dexamethasone intravenously after the onset of anesthesia, and again 24 hours later)
Study: 34237755
Drug: Behavioral and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral and pelvic floor muscle therapy combined with midurethral sling
Study: 39246931
Drug: Placebo (vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle solution)
Study: 35028615
Drug: PXL770 500
Normalized name: PXL770 free acid anhydrous
DrugBank: PXL-770 free acid anhydrous (DB17615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PXL770 500 mg QD
Study: 33236706
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with dual antiparasitic therapy and corticosteroids
Study: 32877425
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy journal app (active control)
Study: 35387431
Drug: Energy Drink
Normalized name: Boost Energy Drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy Drink (3 mg caffeine per kg of body weight)
Study: 33892764
Drug: Constraint-induced Aphasia
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint-induced Aphasia Therapy Plus (CIAT Plus)
Study: 33892764
Drug: Multi-modality Aphasia
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-modality Aphasia Therapy (M-MAT)
Study: 32569239
Drug: Half dose
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half dose of low‐molecular‐weight heparin sodium injection (FLUXUM)
Study: 32569239
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose of low‐molecular‐weight heparin sodium injection (FLUXUM)
Study: 32569239
Drug: Argatroban injection
Normalized name: argatroban Injection
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Argatroban injection
Study: 37452140
Drug: Etoricoxib 90
Normalized name: etoricoxib 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 90 mg
Study: 34851729
Drug: 75 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 μg fentanyl
Study: 35644684
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of iodine intake and excretion increments
Study: 33506195
Drug: Oral sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sedation (lorazepam 1 mg/oxycodone 5 mg)
Study: 34874654
Drug: Cytoflavin tablets,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin tablets, 2 tablets 2 times a day for 25 days
Study: 34874654
Drug: Other drugs
Normalized name: Other drugs for bile therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other drugs (vitamins, nootropic drugs)
Study: 36374982
Drug: Cordyceps cicadae
Normalized name: Cicada periostracum extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cordyceps cicadae mycelium supplementation (1,050 mg daily for 90 days)
Study: 32661006
Drug: Interferon β‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon β‐1a (IFN β‐1a) administered at a dose of 44-μg/ml (12 million IU/ml) subcutaneously injected three times weekly for two consecutive weeks, in addition to national protocol medications (hydroxychloroquine plus lopinavir-ritonavir or atazanavir-ritonavir)
Study: 32661006
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received only national protocol medications (hydroxychloroquine plus lopinavir-ritonavir or atazanavir-ritonavir)
Study: 32390248
Drug: Tolperisone (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolperisone (150 mg TID)
Study: 32390248
Drug: Cyclobenzaprine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclobenzaprine (10 mg TID)
Study: 33078467
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy (CPT) - Group format
Study: 33078467
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy (CPT) - Individual format
Study: 33078467
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy (CPT) - Both formats (Group and Individual)
Study: 35694708
Drug: Self-made Hewei
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-made Hewei decoction plus conventional western medicine
Study: 34301974
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg escitalopram for 7 days
Study: 35644305
Drug: GDC-4379 10
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GDC-4379 10 mg QD
Study: 35644305
Drug: GDC-4379 30
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GDC-4379 30 mg QD
Study: 35644305
Drug: GDC-4379 40
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GDC-4379 40 mg BID
Study: 35644305
Drug: GDC-4379 80
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GDC-4379 80 mg QD
Study: 36899369
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg once daily
Study: 34304419
Drug: MR and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR and JVE‐L combined vaccination group (experimental group)
Study: 36382660
Drug: Oral counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral counseling
Study: 32651768
Drug: Racemic epinephrine
Normalized name: EPINEPHRINE,RACEMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic epinephrine (RE) nebulization, 0.2 ml of RE added to 1.8 ml of distilled water, re-administered if needed on 6 h.
Study: 32651768
Drug: 3% hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% hypertonic saline (HS) nebulization, 2 ml of 3% HS nebulized, frequency of 1 to 4 h.
Study: 33704494
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplements (LNSs)
Study: 33075621
Drug: rice with
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rice with sugar solution (PSS + R)
Study: 39304237
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous sulphate
Study: 36271471
Drug: TransCon PTH
Normalized name: TransCon PTH
DrugBank: Palopegteriparatide (DB18676)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TransCon PTH (18 μg/d)
Study: 33794354
Drug: Switch medications
Normalized name: witch hazel Medicated Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch medications from NRT to varenicline
Study: 33794354
Drug: Intensify treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensify treatment to a higher CM reward schedule
Study: 35780589
Drug: QLC (Qilong
Approvals — FDA: no, EMA: no, PMDA: no
Description: QLC (Qilong capsule) combined with conventional treatment (CT)
Study: 34728131
Drug: Neoadjuvant and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant and concurrent androgen deprivation therapy (ADT) for 6 months starting 4 months before prostate radiotherapy
Study: 34728131
Drug: Concurrent and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent and adjuvant ADT for 6 months starting simultaneously with prostate radiotherapy
Study: 32796442
Drug: Intravitreal dexamethasone
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal dexamethasone implant injection
Study: 35807864
Drug: Calcitriol treatment
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcitriol treatment (in vitro)
Study: 36314323
Drug: CIRRHOS product
Normalized name: Fritillaria cirrhosa bulb extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIRRHOS product (2 gr L-carnitine and 150 mg magnesium) for 16 weeks
Study: 37604396
Drug: Lozenge containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lozenge containing 2% arginine and probiotics (Lacticaseibacillus rhamnosus, LGG® and Lactobacillus paracasei subsp. paracasei)
Study: 33549047
Drug: Fecal microbiota
Normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal microbiota transplantation (FMT) capsules, administered once a week for 4 consecutive weeks
Study: 33549047
Drug: Placebo capsules,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules, administered once a week for 4 consecutive weeks
Study: 35209934
Drug: Fecal microbiota
Normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal microbiota transplantation (FMT) capsules
Study: 32140867
Drug: Morning administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning administration of IFN‐β1a 44 µg (Rebif)
Study: 32140867
Drug: Evening administration
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening administration of IFN‐β1a 44 µg (Rebif)
Study: 35822289
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (OC) during hypercapnia
Study: 35822289
Drug: Not taking
Normalized name: Lamictal 25mg-100mg Tablet Starter Kit (For Patients Not Taking Enzyme-Inducing Drugs or Valproate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not taking oral contraceptives (NOC) during hypercapnia
Study: 36376830
Drug: Arginine‐containing toothpaste,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arginine‐containing toothpaste, Colgate Total Daily Repair (PC)
Study: 36376830
Drug: Fluoride‐free toothpaste,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride‐free toothpaste, Colgate Oral Care (NC)
Study: 32232363
Drug: Glucagon (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon (2 pmol/kg/min intravenous infusion)
Study: 32232363
Drug: Vehicle infusion
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle infusion (rate-matched)
Study: 33187503
Drug: Hypnotherapeutic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnotherapeutic group program (5 weekly sessions of 120-min duration, plus 5 hypnosis audiorecords for individual practice at home, plus an educational booklet for stress coping)
Study: 35450813
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PCAT-RCA of ≥−70.5 HU and LAP burden >4%
Study: 35450813
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of LAP burden and PCAT attenuation
Study: 35627704
Drug: Kitchen diet
Normalized name: Kitchen sage oil
DrugBank: Sage oil (DB11199)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kitchen diet (n = 32; 1.2 g fiber in 100 mL)
Study: 35627704
Drug: Nutrison Energy®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrison Energy® (n = 14; 0.02 g fiber in 100 mL)
Study: 35627704
Drug: Nutrison Diason
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrison Diason Energy HP® (n = 13; 1.8 g fiber in 100 mL)
Study: 34848169
Drug: Ranibizumab 0.5
Normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.5 mg every 4 weeks (Rq4)
Study: 32768938
Drug: Pure western
Normalized name: Dream Pure BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure western medicine therapy (PWM group)
Study: 33080291
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg nicotine
Study: 36209381
Drug: Fractional CO2
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional CO2 laser treatment followed by topical application of triamcinolone acetonide
Study: 36209381
Drug: Dermapen treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermapen treatment followed by topical application of triamcinolone acetonide
Study: 36966023
Drug: Dexamethasone 0.15
Normalized name: dexamethasone 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.15 mg/kg
Study: 33719795
Drug: Digital Cognitive
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital Cognitive Behavioral Therapy for Insomnia (CBTI)
Study: 33481328
Drug: sorafenib +
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorafenib + vitamin K2 (menatetrenone, 45 mg daily, orally)
Study: 36100413
Drug: 20% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% glucose solution
Study: 35904046
Drug: Esketamine nasal
Normalized name: esketamine Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine nasal spray (ESK) plus standard of care (SoC)
Study: 35904046
Drug: Placebo nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray (PBO) plus standard of care (SoC)
Study: 32598909
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone 600 mg per day from 11 to 14 until 34 weeks’ gestation
Study: 39680411
Drug: CBD 400
Normalized name: CBD
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CBD 400 mg
Study: 34719731
Drug: THC 8
Normalized name: THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: THC 8 mg + CBD 4 mg (THC + CBDlow)
Study: 34719731
Drug: THC 12
Normalized name: THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: THC 12 mg + CBD 400 mg (THC + CBDhigh)
Study: 32438716
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PBMT) with laser irradiation, applied on days 0, 3, 7, and 14 for 2-4 minutes each session
Study: 33973828
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy using 660, 800, and 970 nm wavelengths with 30 kJ of energy for 3 minutes
Study: 34193163
Drug: Government supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Government supplements due to SARS-CoV-2 pandemic
Study: 34808036
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg fenofibrate
Study: 33210772
Drug: Risk indicator
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Risk indicator - Implant malposition (too vestibular)
Study: 33210772
Drug: Risk indicator
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Risk indicator - Implant brand (Nobel vs. Straumann)
Study: 33210772
Drug: Protective indicator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protective indicator - Proton pump inhibitors
Study: 33210772
Drug: Protective indicator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protective indicator - Anticoagulants
Study: 34636710
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (group therapy on diet and physical activity modification)
Study: 32551827
Drug: Hatha yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hatha yoga classes (25 minutes, twice weekly for 12 weeks)
Study: 32341237
Drug: Polaprezinc (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polaprezinc (150 mg/d) plus pantoprazole (40 mg/d)
Study: 32341237
Drug: Rebamipide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebamipide (300 mg/d) plus pantoprazole (40 mg/d)
Study: 32312302
Drug: Routine care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine care + daily motivational e-messages to maintain the log book
Study: 32312302
Drug: Routine care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine care + e-device for measuring step count (fit bit) + daily motivational e-messages
Study: 36378671
Drug: Aleglitazar (PPAR-α/γ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aleglitazar (PPAR-α/γ agonist)
Study: 36068298
Drug: Catecholamines (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catecholamines (specific dosage and duration not mentioned)
Study: 32645137
Drug: GDF‐15 levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDF‐15 levels in the highest quartile (≥358 pg/mL)
Study: 33805883
Drug: β-Hydroxy-β-Methylbutyrate (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-Hydroxy-β-Methylbutyrate (7.5 g) and L-Arginine α-Ketoglutarate (10 g) supplementation
Study: 32315057
Drug: Intravenous zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous zoledronic acid (5 mg in 100 mL saline solution)